Results 191 to 200 of about 443,339 (310)
Human immunodeficiency virus recency testing coverage and partner-notification-services among people-living with human immunodeficiency virus in low- and middle-income countries. [PDF]
El-Imam IA +9 more
europepmc +1 more source
Human Immunodeficiency Virus (HIV) [PDF]
openaire +2 more sources
Tuberculosis and tuberculosis-human immunodeficiency virus in post-conflict West Africa: Lessons for integrated surveillance from 2000 to 2022. [PDF]
Duah JK.
europepmc +1 more source
What's New? Cancers of the breast and female genital tract represent more than half of all cancers in women in sub‐Saharan Africa. Here, the authors assessed incidence trends in a female population living in urban sub‐Saharan Africa based on the Zimbabwe National Cancer Registry in Harare over a 30‐year period.
Eric Chokunonga +7 more
wiley +1 more source
Ghanaians living with Human Immunodeficiency Virus: social determinants of quality of life. [PDF]
Lartey SD +7 more
europepmc +1 more source
What's New? Anal squamous cell carcinoma (ASCC) incidence is increasing, with most cases occurring in immunocompetent women. ASCC risk is linked in particular to genital human papillomavirus (HPV) infection and HPV‐associated high‐grade squamous intraepithelial lesions (HSILs).
Isabel Matas +13 more
wiley +1 more source
Diagnostic challenges for a case of maxillary carcinoma cuniculatum in the setting of human immunodeficiency virus: a case report. [PDF]
Figueroa-Ortiz JX +3 more
europepmc +1 more source
in c.o.l.l. con Italian Register for Human Immunodeficiency Virus Infection in Children +1 more
core
Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium
In recent years, incorporating comprehensive cancer screening strategies into routine HIV care has gained growing attention. This survey of 220 sites providing HIV care across 41 countries shows that cervical cancer screening has increased in availability over time.
Rachael A. Pellegrino +32 more
wiley +1 more source
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim +22 more
wiley +1 more source

